CollPlant Biotechnologies Q3 Adj EPS $(0.35) Misses $(0.13) Estimate, Sales $43.00K Miss $3.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
CollPlant Biotechnologies (NASDAQ:CLGN) reported a Q3 adjusted EPS loss of $(0.35), significantly missing the $(0.13) estimate, and sales of $43.00K, falling short of the $3.50M estimate. Compared to last year, EPS decreased by 2.94%, and sales dropped by 60.55%.
November 29, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CollPlant Biotechnologies reported a larger-than-expected loss per share and a significant miss in sales for Q3, indicating potential financial challenges.
The substantial miss in both EPS and revenue compared to analyst estimates suggests that the company is underperforming and may face investor concerns over its financial health and growth prospects. This could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100